MBOT Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -- compared to Microbot Medical's net margin of 8.28%. Microbot Medical's return on equity of -- beat Globus Medical's return on equity of 2.27%.

Microbot Medical has a consensus price target of --, signalling upside risk potential of 618.32%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 14.04%. Given that Microbot Medical has higher upside potential than Globus Medical, analysts believe Microbot Medical is more attractive than Globus Medical.

Microbot Medical has a beta of 1.619, which suggesting that the stock is 61.938% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Microbot Medical quarterly revenues are --, which are smaller than Globus Medical quarterly revenues of $625.7M. Microbot Medical's net income of -$3.2M is lower than Globus Medical's net income of $51.8M. Notably, Microbot Medical's price-to-earnings ratio is -- while Globus Medical's PE ratio is 123.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 4.57x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience has a net margin of -- compared to Microbot Medical's net margin of -40.91%. Microbot Medical's return on equity of -- beat Twist Bioscience's return on equity of -38.12%.

Microbot Medical has a consensus price target of --, signalling upside risk potential of 618.32%. On the other hand Twist Bioscience has an analysts' consensus of -- which suggests that it could grow by 7.96%. Given that Microbot Medical has higher upside potential than Twist Bioscience, analysts believe Microbot Medical is more attractive than Twist Bioscience.

Microbot Medical has a beta of 1.619, which suggesting that the stock is 61.938% more volatile than S&P 500. In comparison Twist Bioscience has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.223%.

Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Twist Bioscience pays out -- of its earnings as a dividend.

Microbot Medical quarterly revenues are --, which are smaller than Twist Bioscience quarterly revenues of $84.7M. Microbot Medical's net income of -$3.2M is higher than Twist Bioscience's net income of -$34.7M. Notably, Microbot Medical's price-to-earnings ratio is -- while Twist Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 8.90x for Twist Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Microbot Medical's net margin of -4291.67%. Microbot Medical's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Microbot Medical has a consensus price target of --, signalling upside risk potential of 618.32%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Microbot Medical has higher upside potential than Catheter Precision, analysts believe Microbot Medical is more attractive than Catheter Precision.

Microbot Medical has a beta of 1.619, which suggesting that the stock is 61.938% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Microbot Medical quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $96K. Microbot Medical's net income of -$3.2M is higher than Catheter Precision's net income of -$4.1M. Notably, Microbot Medical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Microbot Medical's net margin of -17.98%. Microbot Medical's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Microbot Medical has a consensus price target of --, signalling upside risk potential of 618.32%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Microbot Medical has higher upside potential than Xtant Medical Holdings, analysts believe Microbot Medical is more attractive than Xtant Medical Holdings.

Microbot Medical has a beta of 1.619, which suggesting that the stock is 61.938% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Microbot Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Microbot Medical quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Microbot Medical's net income of -$3.2M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Microbot Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical is -- versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.